In today’s recent session, 1.0 million shares of the Relay Therapeutics Inc (NASDAQ:RLAY) have been traded, and its beta is 1.64. Most recently the company’s share price was $3.77, and it changed around $0.03 or 0.80% from the last close, which brings the market valuation of the company to $646.34M. RLAY at last check was trading at a discount to its 52-week high of $10.72, offering almost -184.35% off that amount. The share price’s 52-week low was $1.77, which indicates that the recent value has risen by an impressive 53.05% since then. We note from Relay Therapeutics Inc’s average daily trading volume that its 10-day average is 3.48 million shares, with the 3-month average coming to 2.09 million.
Relay Therapeutics Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.45. If we narrow it down even further, the data shows that 0 out of 13 analysts rate the stock as a Sell; another 5 rate it as Overweight. Among the rest, 2 recommended RLAY as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight.
Relay Therapeutics Inc (NASDAQ:RLAY) trade information
Instantly RLAY has been showing a green trend so far today with a performance of 0.80% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 3.97 on recent trading dayincreased the stock’s daily price by 5.04%. The company’s shares are currently down -57.78% year-to-date, but still up 3.86% over the last five days. On the other hand, Relay Therapeutics Inc (NASDAQ:RLAY) is 13.55% up in the 30-day period. We can see from the shorts that 21.52 million shares have been sold at a short interest cover period of 13.74 day(s).
The consensus price target as assigned by Wall Street analysts is $19, which translates to bulls needing to increase their stock price by 80.16% from its current value. Analyst projections state that RLAY is forecast to be at a low of $16 and a high of $25.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -23.05%. Relay Therapeutics Inc earnings are expected to increase by 20.84% in 2025, but the outlook is positive 10.39% per year for the next five years.
RLAY Dividends
Relay Therapeutics Inc’s next quarterly earnings report is expected to be released on 2025-Jun-03.
Relay Therapeutics Inc (NASDAQ:RLAY)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 1.48% of Relay Therapeutics Inc shares, and 105.71% of them are in the hands of institutional investors. The stock currently has a share float of 107.29%. Relay Therapeutics Inc stock is held by 293.0 institutions, with SB INVESTMENT ADVISERS (UK) LTD being the largest institutional investor. By 2024-06-30, it held 21.0093% of the shares, which is about 27.9 million shares worth $181.94 million.
VANGUARD GROUP INC, with 8.8125% or 11.7 million shares worth $76.32 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF were the top two Mutual Funds as of Mar 31, 2025 . The former held 4.99 shares worth $18.99 million, making up 2.91% of all outstanding shares. On the other hand, iShares Trust-iShares Russell 2000 ETF held roughly 3.3 shares worth around $12.57 million, which represents about 1.93% of the total shares outstanding.
